Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 7.5% – What’s Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX) traded down 7.5% during mid-day trading on Monday . The stock traded as low as $12.31 and last traded at $12.30. 21,717 shares were traded during trading, a decline of 94% from the average session volume of 356,558 shares. The stock had previously closed at $13.30.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BCAX shares. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. HC Wainwright lifted their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Wedbush restated an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. Finally, Rodman & Renshaw started coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Stock Down 4.5 %

The firm’s 50 day simple moving average is $13.94.

Hedge Funds Weigh In On Bicara Therapeutics

Large investors have recently bought and sold shares of the company. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics during the fourth quarter worth about $31,000. BNP Paribas Financial Markets acquired a new stake in Bicara Therapeutics during the 4th quarter worth approximately $32,000. Legal & General Group Plc bought a new stake in Bicara Therapeutics during the 4th quarter worth approximately $33,000. Summit Investment Advisors Inc. acquired a new position in Bicara Therapeutics in the 4th quarter valued at approximately $35,000. Finally, Virtus ETF Advisers LLC acquired a new position in Bicara Therapeutics in the 4th quarter valued at approximately $69,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.